This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Dietrich A. Stephan
Chairman and CEO at NeuBase Therapeutics


Dr. Stephan is the founder, CEO and Chairman of NeuBase Therapeutics. NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders and cancers. Dr. Stephan is an industry veteran who is considered one of the fathers of the field of precision medicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research at the Translational Genomics Research Institute where he oversaw 500 scientists and thirteen divisions, and subsequently served as professor and chairman of Human Genetics at the University of Pittsburgh/UPMC, a top 5 ranked academic medical center. Stephan’s teams have identified the molecular basis of dozens of genetic diseases and published extensively in journals such as Science, the New England Journal of Medicine, Nature Genetics, the Proceedings of the National Academy of Science and Cell. In parallel, Dr. Stephan has founded or co-founded 14 biotechnology companies based on his insights into the pathogenesis of diseases and has advised an additional 12 companies. Many of these companies have become segment-defining. These companies are backed by the top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures as well as corporate partners such as Life Technologies, Pfizer, and Mayo Clinic and have generated significant investor returns. For his contributions to improving patient lives across the globe, Dr. Stephan has won multiple awards and been profiled extensively in the lay media including twice on the front page of the Wall Street Journal. Dr. Stephan received his Ph.D. from the University of Pittsburgh and his BS from Carnegie Mellon University.

Dietrich A. Stephan's Network

Agenda Sessions

  • The coming of age of RNA Medicines - Hilton Union Square